A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 26, Issue 4, 2008, Pages 381-386

  Cohn, Allen L ^a,b   Myers, J William ^a,c   Mamus, Steven ^a,d   Deur, Charles ^a,c   Nicol, Steven ^e   Hood, Karen ^e   Khan, Muhammad M ^a   Ilegbodu, Des ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b ROCKY MOUNTAIN CANCER CENTERS   (United States)

^c TEXAS ONCOLOGY   (United States)

^d Cancer Centers of Florida   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Hepatocellular carcinoma; Metastatic; Pemetrexed; Phase II

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN B 12;

EID: 45849097147     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9124-5     Document Type: Article

References (22)

1. American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta, GA (p. 4)
2. American Cancer Society (2005) Cancers linked to infectious disease. In: American Cancer Society Cancer facts and figures 2005. American Cancer Society, Atlanta, GA, pp 22-34
3. Surveillance, Epidemiology and End Results (SEER) program. SEER*Stat database. Cancer of the Liver and Intrahepatic Bile Duct. Available from URL: http://seer.cancer.gov/statfacts/html/livibd.html. Accessed December 8, 2006
4. Burroughs A, Hochhauser D, Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5:409-418
5. Cheng AL, Yeh KH, Fine RL, Chuang SE, Yang CH, Wang LH, Chen DS (1998) Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 45:1955-1960
6. Melia WM, Johnson PJ, Williams R (1987) Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71:1213-1216
7. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ (2002) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94:421-427
8. Jiang W, Lu Z, He Y, Diasio RB (1997) Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395-399
9. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 101:578-586
10. Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD (1999) Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 44:105-110
11. Rhee MS, Ryan TJ, Galivan J (1999) Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 44:427-432
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubenstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
13. Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, de Bono J, Tolcher AW, Patnaik A, Monroe P, Wood L, Schneck KB, Clark R, Rowinsky EK (2007) Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 13(9):2675-2683
14. Grindey GB, Shih C, Barnett CJ, Pearce HL, Engelhardt JA, Todd GC, Rinzel SM, Worzalla JF, Gossett LS, Everson TP (1992) LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33:411
15. Meriggi F, Di Biasi B, Caliolo C, Zaniboni A (2008) The potential role of pemetrexed in gastrointestinal cancer. Chemotherapy 54(1):1-8
16. Llombart-Cussac A, Martin M, Harbeck N, Anghel RM, Eniu AE, Verrill MW, Neven P, De Grève J, Melemed AS, Clark R, Simms L, Kaiser CJ, Ma D (2007) A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 13(12):3652-3659
17. Louvet C, de Gramont A (2004) Pemetrexed in advanced colorectal cancer. Oncology 18(13 Suppl 8):56-62
18. Goedhals L, van Wiyk AL, Smith BL, Fourie SJ (2006) Pemetrexed (Alimta®, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer 16:1172-1178
19. Carr BI (2004) Hepatocellular carcinoma: current management and future trends. Gastroenterology 127:S218-S224
20. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systemic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25
21. Di Lorenzo G, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, De Stefano A, Esposito V, De Placido S, Montesarchio V (2007) Activity and safety of peglyated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. World J Gastroenterol 13(48):6553-6557
22. Kulik LM, Mulcahy MF, Omary RA, Salem R (2007) Emerging approaches in hepatocellular carcinoma. J Clin Gastroenterol 41:839-854